Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genmab Adds Preclinical Assets With iDD Deal

This article was originally published in Scrip

Executive Summary

Antibody drug maker Genmab enhanced its intellectual property portfolio and preclinical pipeline on 18 March, paying €2.5m ($2.66m) upfront to France's iDD Biotech SAS. Under the terms of the deal, Genmab will receive the rights to several antibodies and the related patents that are directed at the DR5 target. DR5, also known as TRAIL Receptor 2, is an emerging cancer target. While the assets are still preclinical, iDD is eligible to receive up to €101.5m in development and sales milestones, as well as single-digit royalties on any products that reach commercialization. The iDD antibodies and patents will complement Genmab's existing portfolio, which includes the already-marketed chronic lymphocytic leukemia drug Arzerra (ofatumumab) and the Phase III multiple myeloma treatment daratumumab (, 04 February 2015).

You may also be interested in...

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.

Update: Ziopharm Study Death Not Due To Drug

The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts